We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

77 hedge funds and large institutions have $247M invested in Immix Biopharma in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 13

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

93% more capital invested

Capital invested by funds: $127M → $247M (+$119M)

15% more funds holding

Funds holding: 67 → 77 (+10)

21.49% less ownership

Funds ownership: 72.62% → 51.12% (-21%)

75% less call options, than puts

Call options by funds: $237K | Put options by funds: $947K

Holders
77
Holders Change
+10
Holders Change %
+14.93%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
28
Reduced
13
Closed
12
Calls
$237K
Puts
$947K
Net Calls
-$710K
Net Calls Change
-$499K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.47M
2
VCIM
Velan Capital Investment Management
Georgia
+$5.18M
3
SVCM
Saturn V Capital Management
Texas
+$5.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.05M
5
GPP
Great Point Partners
Connecticut
+$2.57M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.84M
2
BOCH
Blue Owl Capital Holdings
New York
-$3.22M
3
Marshall Wace
Marshall Wace
United Kingdom
-$2.48M
4
Ameriprise
Ameriprise
Minnesota
-$2.36M
5
PA
Perceptive Advisors
New York
-$1.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.27M +$97.4K +13,264 +10%
Northern Trust
27
Northern Trust
Illinois
$1.26M +$276K +37,574 +37%
EI
28
EAM Investors
California
$1.1M – – –
Goldman Sachs
29
Goldman Sachs
New York
$869K -$830K -112,966 -54%
TAM
30
Tocqueville Asset Management
New York
$816K +$154K +21,000 +31%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$762K -$111K -15,121 -15%
XT
32
XTX Topco
Cayman Islands
$738K +$255K +34,657 +75%
BCM
33
Bridgeway Capital Management
Texas
$729K +$588K +80,000 New
UBS Group
34
UBS Group
Switzerland
$700K +$134K +18,233 +31%
UCFA
35
United Capital Financial Advisors
Texas
$644K – – –
Hudson Bay Capital Management
36
Hudson Bay Capital Management
Connecticut
$578K +$219K +29,852 +89%
BHCM
37
Brevan Howard Capital Management
Jersey
$524K +$422K +57,508 New
PWM
38
Palumbo Wealth Management
New York
$503K +$406K +55,232 New
TD Asset Management
39
TD Asset Management
Ontario, Canada
$485K +$391K +53,200 New
Barclays
40
Barclays
United Kingdom
$472K +$123K +16,768 +48%
VF
41
Virtu Financial
New York
$438K -$189K -25,682 -35%
Citadel Advisors
42
Citadel Advisors
Florida
$430K -$207K -28,165 -37%
Squarepoint
43
Squarepoint
New York
$405K +$169K +22,990 +107%
Bank of America
44
Bank of America
North Carolina
$375K +$302K +41,115 +256,969%
Jane Street
45
Jane Street
New York
$320K -$969K -131,968 -79%
C
46
Certuity
Florida
$319K +$257K +35,000 New
PAG
47
Private Advisor Group
New Jersey
$316K +$22K +3,000 +9%
IW
48
Imprint Wealth
South Carolina
$285K +$82.5K +11,239 +56%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$264K +$213K +28,964 New
Charles Schwab
50
Charles Schwab
California
$250K +$202K +27,462 New
1
2
3 4

IMMX Hedge Fund Activity: Q1 2026 in Review

77 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2026, worth a combined $247M — up 93% from $127M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new IMMX positions and 12 closed out — a net gain of 12 holders — while 28 added to existing stakes and 13 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $6.47M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $7.84M sold.

  • 77 institutional investors held Immix Biopharma (IMMX) as of Q1 2026, up from 67 in Q4 2025.
  • Funds reported $247M of Immix Biopharma stock for Q1 2026, up 93% quarter-over-quarter.
  • 24 funds opened new Immix Biopharma positions in Q1 2026 and 12 closed out, a net change of +12 holders.
  • The largest Immix Biopharma buyer in Q1 2026 was Janus Henderson Group, an estimated $6.47M added.
  • The largest Immix Biopharma seller in Q1 2026 was Adage Capital Partners, an estimated $7.84M sold.

Based on aggregated 13F filings for Q1 2026.